Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28024474 | 0.85 | KMO (0.58) | KMOADORA2AAURKAHSP90AA1PRKACA | |
| SCHEMBL9792898 | 0.81 | KMO (0.59) | KMOCTSKCTSSMAPK1IRAK4 | |
| SCHEMBL31086625 | 0.81 | MAOB (0.55) | KMOMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL29254839 | 0.81 | MAOB (0.55) | KMOMEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL28844124 | 0.80 | KMO (0.57) | KMOPRKACACTSKMEN1KMT2A | |
| SCHEMBL31754502 | 0.79 | KDM4E (0.55) | KMOHSP90AA1MEN1KMT2ARAB9A | |
| SCHEMBL18535 | 0.76 | CTSS (0.63) | KMOCTSKCTSSIRAK4 | |
| SCHEMBL8842521 | 0.75 | ABCG2 (0.62) | ADORA2AAURKAHSP90AA1PRKACAMEN1 | |
| SCHEMBL14484877 | 0.75 | KMO (0.45) | KMOCTSKMEN1KMT2ARAB9A | |
| SCHEMBL22738478 | 0.74 | KMO (0.51) | KMOCTSKMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928842-B1 | 4-PHENYL-6-SUBSTITUTED-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2009-11-18 | — | — | EP | claimed |
| US-7589095-B2 | 4-phenyl-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2009-09-15 | — | — | US | claimed |
| EP-1758870-B1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2008-08-13 | — | — | EP | claimed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | claimed |
| CN-1980897-A | 4-phenyl-pyrimidine-2-carbonitrile derivatives | ORGANON NV (NL) | 2007-06-13 | — | — | CN | claimed |
| EP-1758870-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2007-03-07 | — | — | EP | claimed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | claimed |
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| CN-112513030-A | Quinoline derivatives as tyrosine kinase inhibitors | 里格尔药品股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-2470012-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| CN-1980897-A | 4-phenyl-pyrimidine-2-carbonitrile derivatives | ORGANON NV (NL) | 2007-06-13 | — | — | CN | disclosed |
| CN-1980897-A | 4-phenyl-pyrimidine-2-carbonitrile derivatives | ORGANON NV (NL) | 2007-06-13 | — | — | CN | disclosed |
| CN-1980897-A | 4-phenyl-pyrimidine-2-carbonitrile derivatives | ORGANON NV (NL) | 2007-06-13 | — | — | CN | disclosed |
| EP-1758870-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2007-03-07 | — | — | EP | disclosed |
| EP-1758870-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851093-B2 | Tyrosine kinase inhibitors | TYRO3, RET, AXL | KMO 398/4885ADORA2A 385/4885AURKA 809/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | KMO 398/4885ADORA2A 385/4885AURKA 809/4885 |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | P2RY4, P2RX4, P2RY1 | KMO 1791/4885ADORA2A 497/4885AURKA 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.